You are here: Home » Reuters » News
Business Standard

New GSK shingles vaccine off to strong start in key U.S. market

Reuters  |  LONDON 

By Ben HirschlerLONDON (Reuters) - GlaxoSmithKline's new shingles vaccine - a priority product as the company strives to improve its drugs line-up - has won more than 90 percent U.S. market share just five months after its launch, prescription-tracking data show.The healthy take-up comes at the expense of Merck & Co's older and less effective product Zostavax, which has seen a slump in demand.The U.S. Centers for Disease Control and Prevention has recommended Shingrix over Zostavax in adults 50 years and older, spurring demand for the GSK vaccine.Deutsche Bank analysts said on Tuesday the ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Tue, April 10 2018. 22:29 IST